Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the acceptance of three abstracts that will be presented in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31-June 4, 2024, in Chicago, Illinois.

The posters will include an update from a City of Hope-led Phase 1 study of Calidi's CLD-101 program, focusing on the treatment of recurrent high-grade glioma, now advancing into its fourth cohort of participants. CLD-101 is a cutting-edge therapeutic candidate in Calidi’s NeuroNova program, comprising tumor-tropic neural stem cells (NSCs) that deliver an oncolytic adenovirus – CRAd-S-pk7 – selectively to tumor sites.

Calidi will also present preclinical data highlighting its RTNova delivery platform, a novel systemic enveloped oncolytic virotherapy program designed to target all tumor sites, and its CLD-201 program, which is expected to dose its first patient in a Phase 1 trial in the second half of 2024 subject to Calidi’s ability to raise additional capital.

Details on the posters and corresponding abstracts are shown below.

Poster Title: Phase 1 study of multiple intracerebral doses of a neural stem cell-based oncolytic virotherapy for treatment of recurrent high-grade gliomas
Abstract Number: TPS2102
Session Title: Central Nervous System Tumors
Session Date and Time: June 1, 2024, from 9:00 AM to 12:00 PM CDT

Poster Title: Transforming tumor immune microenvironments with a novel systemic enveloped oncolytic virotherapy targeting all tumor sites
Abstract Number: 2559
Session Title: Developmental Therapeutics – Immunotherapy
Session Date and Time: June 1, 2024, from 9:00 AM to 12:00 PM CDT

Poster Title: Non-clinical evidence supporting the upcoming CLD-201 clinical trial: Cell-based oncolytic virotherapy for multiple solid tumors
Abstract Number: 2553
Session Title: Developmental Therapeutics - Immunotherapy
Session Date and Time: June 1, 2024, from 9:00 AM to 12:00 PM CDT

Copies of the posters will be available on the Publications section of Calidi’s website following presentation at the meeting.

About Calidi Biotherapeutics

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.